Review




Structured Review

Boehringer Ingelheim soluble cd200 fc
Soluble Cd200 Fc, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd200/cd200+fc+soluble/pm41840630-121-2-9
Average 86 stars, based on 1 article reviews
soluble cd200 fc - by Bioz Stars, 2026-11
86/100 stars

Images

Related Articles

Control:

Article Title: Increased soluble CD200 in serum of SLE patients does not reflect disease activity or affect CD200R1 function in T cells.
Article Snippet: On day 7, we refreshed the medium and added IL-4 40ng/ml (RnD systems #204-IL). .. We co-coated maxisorp F-bottom plates (Thermo ScientificTM #442404) with CD200-Fc 15μg/ml in PBS (provided by Boehringer Ingelheim) or CD200R-Fc 15 μg/ml in PBS as control (provided by Boehringer Ingelheim), and antiCD3 1μg/ml (OKT-clone, Invitrogen, #16-0037-85) or IgG2a κ isotype 1μg/ml. ..

Article Title: Increased soluble CD200 in serum of SLE patients does not reflect disease activity or affect CD200R1 function in T cells.
Article Snippet: On day 8, we seeded the cells on maxisorp F-bottom plates (Thermo ScientificTM #442404) coated with antiCD3 1μg/ml (OKT-clone, Invitrogen, #16-0037-85) or IgG2a κ isotype 1μg/ml. .. We added soluble CD200-Fc 15μg/ml in PBS (provided by Boehringer Ingelheim) or CD200R-Fc 15 μg/ml in PBS as control (provided by Boehringer Ingelheim), and .. AR TIC LE IN PR ES S ARTICLE IN PRESS recombinant Human CD200 Protein His Tag 2μg/ml (BioConnect # 10886-H08H).



Similar Products

94
Sino Biological mouse cd200 fc recombinant protein
Mouse Cd200 Fc Recombinant Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd200/Mouse+CD200+Protein/10__1038_slash_s41598___026___68258___3-45-16-21
Average 94 stars, based on 1 article reviews
mouse cd200 fc recombinant protein - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Miltenyi Biotec cd200 antibody, anti-human
Cd200 Antibody, Anti Human, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd200/CD200+Antibody%2C+anti-human/custom%40130-124-277%4042242396
Average 94 stars, based on 1 article reviews
cd200 antibody, anti-human - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Bio X Cell anti cd200 blocking antibody
Anti Cd200 Blocking Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd200/InVivoMAb+anti-mouse+CD200/pm42869916-214-10-16
Average 94 stars, based on 1 article reviews
anti cd200 blocking antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Proteintech mouse anti cd200 antibody
Mouse Anti Cd200 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd200/CD200+Antibody/10__1038_slash_s41598___026___68258___3-45-178-181
Average 93 stars, based on 1 article reviews
mouse anti cd200 antibody - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Sino Biological sino biological cat 50074 m38h
Sino Biological Cat 50074 M38h, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd200/Mouse+CD200+Protein/10__1038_slash_s41598___026___68258___3-45-88-88
Average 94 stars, based on 1 article reviews
sino biological cat 50074 m38h - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
ABclonal Biotechnology cd200
LPS-stimulated AMs cocultured with PD-L1 + PMN-MDSCs exhibit immunosuppressive and exhausted profiles. (A) Principal component analysis ( n = 3). (B) GO enrichment analysis. (C) Volcano plot of differentially expressed genes. (D) Flow cytometric sorting strategy for murine alveolar macrophages. (E) Flow cytometric sorting strategy for alveolar macrophages from bronchoalveolar lavage fluid (BALF) of clinical patients. (F) Protein levels of C1q, LAG3, <t>CD200,</t> S100A8, S100A9, Wnt5a, and LEF1 in LPS-stimulated AMs cocultured or not with PD-L1 + PMN-MDSCs. (G) Protein levels of KLF9, PD-1, C1q, LAG3, and CD200 in flow-sorted AMs from BALF of septic and nonseptic patients. (H) Correlation network of PD-1, Wnt, and classical complement pathways. (I to K) GSEA of complement regulation (I), chemokine receptor binding (J), and PD-1 signaling (K). (L) Flow cytometric gating strategy for identifying PMN-MDSCs (defined as CD45 + CD11b + CD15 + CD14 − CD33 + HLA-DR l ° w ) and the CXCR2 + PD-L1 + subpopulation in the peripheral blood of clinical patients. (M and N) Absolute number of total PMN-MDSCs (M) and CXCR2 + PD-L1 + PMN-MDSCs (N) in peripheral blood from septic and nonseptic patients ( n = 6). Values are mean ± SD. Panels (M) and (N) were analyzed by Student t test. * P < 0.05, ** P < 0.01.
Cd200, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd200/LAG3+Rabbit+pAb/pmc13486733-339-18-20
Average 94 stars, based on 1 article reviews
cd200 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

91
Bio-Techne corporation recombinant human cd200 fc chimera protein, cf
LPS-stimulated AMs cocultured with PD-L1 + PMN-MDSCs exhibit immunosuppressive and exhausted profiles. (A) Principal component analysis ( n = 3). (B) GO enrichment analysis. (C) Volcano plot of differentially expressed genes. (D) Flow cytometric sorting strategy for murine alveolar macrophages. (E) Flow cytometric sorting strategy for alveolar macrophages from bronchoalveolar lavage fluid (BALF) of clinical patients. (F) Protein levels of C1q, LAG3, <t>CD200,</t> S100A8, S100A9, Wnt5a, and LEF1 in LPS-stimulated AMs cocultured or not with PD-L1 + PMN-MDSCs. (G) Protein levels of KLF9, PD-1, C1q, LAG3, and CD200 in flow-sorted AMs from BALF of septic and nonseptic patients. (H) Correlation network of PD-1, Wnt, and classical complement pathways. (I to K) GSEA of complement regulation (I), chemokine receptor binding (J), and PD-1 signaling (K). (L) Flow cytometric gating strategy for identifying PMN-MDSCs (defined as CD45 + CD11b + CD15 + CD14 − CD33 + HLA-DR l ° w ) and the CXCR2 + PD-L1 + subpopulation in the peripheral blood of clinical patients. (M and N) Absolute number of total PMN-MDSCs (M) and CXCR2 + PD-L1 + PMN-MDSCs (N) in peripheral blood from septic and nonseptic patients ( n = 6). Values are mean ± SD. Panels (M) and (N) were analyzed by Student t test. * P < 0.05, ** P < 0.01.
Recombinant Human Cd200 Fc Chimera Protein, Cf, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd200/Recombinant+Human+CD200+Fc+Chimera+Protein%2C+CF/bio-techne+corporation___2724-cd
Average 91 stars, based on 1 article reviews
recombinant human cd200 fc chimera protein, cf - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

86
Boehringer Ingelheim soluble cd200 fc
LPS-stimulated AMs cocultured with PD-L1 + PMN-MDSCs exhibit immunosuppressive and exhausted profiles. (A) Principal component analysis ( n = 3). (B) GO enrichment analysis. (C) Volcano plot of differentially expressed genes. (D) Flow cytometric sorting strategy for murine alveolar macrophages. (E) Flow cytometric sorting strategy for alveolar macrophages from bronchoalveolar lavage fluid (BALF) of clinical patients. (F) Protein levels of C1q, LAG3, <t>CD200,</t> S100A8, S100A9, Wnt5a, and LEF1 in LPS-stimulated AMs cocultured or not with PD-L1 + PMN-MDSCs. (G) Protein levels of KLF9, PD-1, C1q, LAG3, and CD200 in flow-sorted AMs from BALF of septic and nonseptic patients. (H) Correlation network of PD-1, Wnt, and classical complement pathways. (I to K) GSEA of complement regulation (I), chemokine receptor binding (J), and PD-1 signaling (K). (L) Flow cytometric gating strategy for identifying PMN-MDSCs (defined as CD45 + CD11b + CD15 + CD14 − CD33 + HLA-DR l ° w ) and the CXCR2 + PD-L1 + subpopulation in the peripheral blood of clinical patients. (M and N) Absolute number of total PMN-MDSCs (M) and CXCR2 + PD-L1 + PMN-MDSCs (N) in peripheral blood from septic and nonseptic patients ( n = 6). Values are mean ± SD. Panels (M) and (N) were analyzed by Student t test. * P < 0.05, ** P < 0.01.
Soluble Cd200 Fc, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd200/cd200+fc+soluble/pm41840630-121-2-9
Average 86 stars, based on 1 article reviews
soluble cd200 fc - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Boehringer Ingelheim cd200 fc
LPS-stimulated AMs cocultured with PD-L1 + PMN-MDSCs exhibit immunosuppressive and exhausted profiles. (A) Principal component analysis ( n = 3). (B) GO enrichment analysis. (C) Volcano plot of differentially expressed genes. (D) Flow cytometric sorting strategy for murine alveolar macrophages. (E) Flow cytometric sorting strategy for alveolar macrophages from bronchoalveolar lavage fluid (BALF) of clinical patients. (F) Protein levels of C1q, LAG3, <t>CD200,</t> S100A8, S100A9, Wnt5a, and LEF1 in LPS-stimulated AMs cocultured or not with PD-L1 + PMN-MDSCs. (G) Protein levels of KLF9, PD-1, C1q, LAG3, and CD200 in flow-sorted AMs from BALF of septic and nonseptic patients. (H) Correlation network of PD-1, Wnt, and classical complement pathways. (I to K) GSEA of complement regulation (I), chemokine receptor binding (J), and PD-1 signaling (K). (L) Flow cytometric gating strategy for identifying PMN-MDSCs (defined as CD45 + CD11b + CD15 + CD14 − CD33 + HLA-DR l ° w ) and the CXCR2 + PD-L1 + subpopulation in the peripheral blood of clinical patients. (M and N) Absolute number of total PMN-MDSCs (M) and CXCR2 + PD-L1 + PMN-MDSCs (N) in peripheral blood from septic and nonseptic patients ( n = 6). Values are mean ± SD. Panels (M) and (N) were analyzed by Student t test. * P < 0.05, ** P < 0.01.
Cd200 Fc, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd200/cd200+fc+soluble/pm41840630-115-9-15
Average 86 stars, based on 1 article reviews
cd200 fc - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

94
Sino Biological monoclonal anti cd200
LPS-stimulated AMs cocultured with PD-L1 + PMN-MDSCs exhibit immunosuppressive and exhausted profiles. (A) Principal component analysis ( n = 3). (B) GO enrichment analysis. (C) Volcano plot of differentially expressed genes. (D) Flow cytometric sorting strategy for murine alveolar macrophages. (E) Flow cytometric sorting strategy for alveolar macrophages from bronchoalveolar lavage fluid (BALF) of clinical patients. (F) Protein levels of C1q, LAG3, <t>CD200,</t> S100A8, S100A9, Wnt5a, and LEF1 in LPS-stimulated AMs cocultured or not with PD-L1 + PMN-MDSCs. (G) Protein levels of KLF9, PD-1, C1q, LAG3, and CD200 in flow-sorted AMs from BALF of septic and nonseptic patients. (H) Correlation network of PD-1, Wnt, and classical complement pathways. (I to K) GSEA of complement regulation (I), chemokine receptor binding (J), and PD-1 signaling (K). (L) Flow cytometric gating strategy for identifying PMN-MDSCs (defined as CD45 + CD11b + CD15 + CD14 − CD33 + HLA-DR l ° w ) and the CXCR2 + PD-L1 + subpopulation in the peripheral blood of clinical patients. (M and N) Absolute number of total PMN-MDSCs (M) and CXCR2 + PD-L1 + PMN-MDSCs (N) in peripheral blood from septic and nonseptic patients ( n = 6). Values are mean ± SD. Panels (M) and (N) were analyzed by Student t test. * P < 0.05, ** P < 0.01.
Monoclonal Anti Cd200, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd200/CD200+%2F+OX-2+Antibody%2C+Rabbit+MAb/pmc13104222-128-11-13
Average 94 stars, based on 1 article reviews
monoclonal anti cd200 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


LPS-stimulated AMs cocultured with PD-L1 + PMN-MDSCs exhibit immunosuppressive and exhausted profiles. (A) Principal component analysis ( n = 3). (B) GO enrichment analysis. (C) Volcano plot of differentially expressed genes. (D) Flow cytometric sorting strategy for murine alveolar macrophages. (E) Flow cytometric sorting strategy for alveolar macrophages from bronchoalveolar lavage fluid (BALF) of clinical patients. (F) Protein levels of C1q, LAG3, CD200, S100A8, S100A9, Wnt5a, and LEF1 in LPS-stimulated AMs cocultured or not with PD-L1 + PMN-MDSCs. (G) Protein levels of KLF9, PD-1, C1q, LAG3, and CD200 in flow-sorted AMs from BALF of septic and nonseptic patients. (H) Correlation network of PD-1, Wnt, and classical complement pathways. (I to K) GSEA of complement regulation (I), chemokine receptor binding (J), and PD-1 signaling (K). (L) Flow cytometric gating strategy for identifying PMN-MDSCs (defined as CD45 + CD11b + CD15 + CD14 − CD33 + HLA-DR l ° w ) and the CXCR2 + PD-L1 + subpopulation in the peripheral blood of clinical patients. (M and N) Absolute number of total PMN-MDSCs (M) and CXCR2 + PD-L1 + PMN-MDSCs (N) in peripheral blood from septic and nonseptic patients ( n = 6). Values are mean ± SD. Panels (M) and (N) were analyzed by Student t test. * P < 0.05, ** P < 0.01.

Journal: Research

Article Title: Splenic PD-L1 + Myeloid-Derived Suppressor Cells Induce Contact-Dependent Alveolar Macrophage Dysfunction in Early Sepsis

doi: 10.34133/research.1407

Figure Lengend Snippet: LPS-stimulated AMs cocultured with PD-L1 + PMN-MDSCs exhibit immunosuppressive and exhausted profiles. (A) Principal component analysis ( n = 3). (B) GO enrichment analysis. (C) Volcano plot of differentially expressed genes. (D) Flow cytometric sorting strategy for murine alveolar macrophages. (E) Flow cytometric sorting strategy for alveolar macrophages from bronchoalveolar lavage fluid (BALF) of clinical patients. (F) Protein levels of C1q, LAG3, CD200, S100A8, S100A9, Wnt5a, and LEF1 in LPS-stimulated AMs cocultured or not with PD-L1 + PMN-MDSCs. (G) Protein levels of KLF9, PD-1, C1q, LAG3, and CD200 in flow-sorted AMs from BALF of septic and nonseptic patients. (H) Correlation network of PD-1, Wnt, and classical complement pathways. (I to K) GSEA of complement regulation (I), chemokine receptor binding (J), and PD-1 signaling (K). (L) Flow cytometric gating strategy for identifying PMN-MDSCs (defined as CD45 + CD11b + CD15 + CD14 − CD33 + HLA-DR l ° w ) and the CXCR2 + PD-L1 + subpopulation in the peripheral blood of clinical patients. (M and N) Absolute number of total PMN-MDSCs (M) and CXCR2 + PD-L1 + PMN-MDSCs (N) in peripheral blood from septic and nonseptic patients ( n = 6). Values are mean ± SD. Panels (M) and (N) were analyzed by Student t test. * P < 0.05, ** P < 0.01.

Article Snippet: Membranes were incubated overnight at 4 °C with antibodies against C1qa (1:1,000, Proteintech, #11602-1-AP), LAG3 (1:1,000, Abclonal, #A2996), CD200 (1:1,000, Abclonal, #A23050), S100A8 (1:1,000, Abclonal, #A15315), S100A9 (1:1,000, Abclonal, #A9842), Wnt5A (1:1,000, Zen Bio, #619919), LEF1 (1:500, Proteintech, #14972-1-AP), KLF9 (1:1,000, Abclonal, #A7196), PD-1 (1:1,000, Abclonal, #A11973), PD-L1 (1:1,000, Abclonal, #A21443), IL-6 (1:1,000, Abcam, #ab229381), TFDP1 (1:1,000, Abclonal, #A5422), IL-10 (1:1,000, Abclonal, #a12255), TGF-β (1:1,000, Abcam, #ab64715), TNF-α (1:1,000, Abclonal, #A11534), PCNA (1:500, Proteintech, #10205-2-AP), or β-actin (1:4,000, Proteintech, #66009-1-Ig).

Techniques: Binding Assay

Myeloid PD-1 deficiency improves outcomes after polymicrobial sepsis and Pseudomonas aeruginosa infection. (A) Protein levels of PD-1, C1qa, CD200, and LAG3 in flow-sorted AMs from Pdcd1 flox/flox and Lyz2 Cre Pdcd1 flox/flox mice post-CLP ( n = 6). (B) Kaplan–Meier survival analysis following P. aeruginosa infection ( n = 21). (C to F) Core body temperature ( n = 16 to 18) (C), bacterial lung burden ( n = 7) (D), and BALF levels of TNF-α ( n = 7) (E) and IL-6 ( n = 7) (F), in septic mice 1 d after P. aeruginosa infection. (G) Lung H&E images and histological injury scoring ( n = 7). (H) Immunofluorescence images and semiquantitative analysis of NET formation using Cit-H3 and MPO staining ( n = 6). Scale bar, 50 μm. (I) Parabiosis and CLP workflow. (J and K) Example FCM plots (J) and proportions of partner-derived neutrophils, IMs, and AMs in lung ( n = 5) (K). (L) Schematics of parabiosis of Pdcd1 flox/flox and Lyz2 Cre Pdcd1 flox/flox mice. (M) BALF TNF-α and IL-6 in septic parabionts after P. aeruginosa infection ( n = 7). Values are mean ± SD. Panel (A) was analyzed by one-way ANOVA with Tukey’s post hoc test; panel (B) was analyzed by log-rank (Mantel–Cox) test; panels (C) to (H) and (M) were analyzed by Student t test. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. ns, not significant.

Journal: Research

Article Title: Splenic PD-L1 + Myeloid-Derived Suppressor Cells Induce Contact-Dependent Alveolar Macrophage Dysfunction in Early Sepsis

doi: 10.34133/research.1407

Figure Lengend Snippet: Myeloid PD-1 deficiency improves outcomes after polymicrobial sepsis and Pseudomonas aeruginosa infection. (A) Protein levels of PD-1, C1qa, CD200, and LAG3 in flow-sorted AMs from Pdcd1 flox/flox and Lyz2 Cre Pdcd1 flox/flox mice post-CLP ( n = 6). (B) Kaplan–Meier survival analysis following P. aeruginosa infection ( n = 21). (C to F) Core body temperature ( n = 16 to 18) (C), bacterial lung burden ( n = 7) (D), and BALF levels of TNF-α ( n = 7) (E) and IL-6 ( n = 7) (F), in septic mice 1 d after P. aeruginosa infection. (G) Lung H&E images and histological injury scoring ( n = 7). (H) Immunofluorescence images and semiquantitative analysis of NET formation using Cit-H3 and MPO staining ( n = 6). Scale bar, 50 μm. (I) Parabiosis and CLP workflow. (J and K) Example FCM plots (J) and proportions of partner-derived neutrophils, IMs, and AMs in lung ( n = 5) (K). (L) Schematics of parabiosis of Pdcd1 flox/flox and Lyz2 Cre Pdcd1 flox/flox mice. (M) BALF TNF-α and IL-6 in septic parabionts after P. aeruginosa infection ( n = 7). Values are mean ± SD. Panel (A) was analyzed by one-way ANOVA with Tukey’s post hoc test; panel (B) was analyzed by log-rank (Mantel–Cox) test; panels (C) to (H) and (M) were analyzed by Student t test. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. ns, not significant.

Article Snippet: Membranes were incubated overnight at 4 °C with antibodies against C1qa (1:1,000, Proteintech, #11602-1-AP), LAG3 (1:1,000, Abclonal, #A2996), CD200 (1:1,000, Abclonal, #A23050), S100A8 (1:1,000, Abclonal, #A15315), S100A9 (1:1,000, Abclonal, #A9842), Wnt5A (1:1,000, Zen Bio, #619919), LEF1 (1:500, Proteintech, #14972-1-AP), KLF9 (1:1,000, Abclonal, #A7196), PD-1 (1:1,000, Abclonal, #A11973), PD-L1 (1:1,000, Abclonal, #A21443), IL-6 (1:1,000, Abcam, #ab229381), TFDP1 (1:1,000, Abclonal, #A5422), IL-10 (1:1,000, Abclonal, #a12255), TGF-β (1:1,000, Abcam, #ab64715), TNF-α (1:1,000, Abclonal, #A11534), PCNA (1:500, Proteintech, #10205-2-AP), or β-actin (1:4,000, Proteintech, #66009-1-Ig).

Techniques: Infection, Immunofluorescence, Staining, Derivative Assay

TFDP1 and S100A9 promote expansion and immunosuppression of splenic PD-L1 + PMN-MDSCs in early sepsis. (A and B) Western blot and quantification of TFDP1 (A) ( n = 6) and S100A9 (B) ( n = 6) in spleens. (C) Schematic of CLP modeling, Adv-shRNA (Tfdp1) treatment, and tissue collection in WT mice. (D) Example FCM plots and percentage of Ki67 in splenic PD-L1 + PMN-MDSCs ( n = 8). (E) Example FCM plots and percentage of PD-L1 in pulmonary PMN-MDSCs ( n = 6). (F) Schematic of CLP modeling, Adv-shRNA ( S100a9 ) treatment, and tissue collection in WT mice. (G) Example FCM plots and percentage of PD-L1 in splenic PMN-MDSCs ( n = 9). (H) Schematic of CLP modeling, Adv-shRNA ( S100a9 ) treatment, and tissue collection in Kaede-tg mice. (I) Example FCM plots and percentage of Kaede red + in pulmonary PD-L1 + PMN-MDSCs ( n = 7 to 8). (J) FCM analysis using t-SNE algorithm showing expressions of PD-1, Lag3, and CD200 in pulmonary AMs ( n = 9 to 10). Values are shown as mean ± SD; statistical testing was determined using Student t test. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

Journal: Research

Article Title: Splenic PD-L1 + Myeloid-Derived Suppressor Cells Induce Contact-Dependent Alveolar Macrophage Dysfunction in Early Sepsis

doi: 10.34133/research.1407

Figure Lengend Snippet: TFDP1 and S100A9 promote expansion and immunosuppression of splenic PD-L1 + PMN-MDSCs in early sepsis. (A and B) Western blot and quantification of TFDP1 (A) ( n = 6) and S100A9 (B) ( n = 6) in spleens. (C) Schematic of CLP modeling, Adv-shRNA (Tfdp1) treatment, and tissue collection in WT mice. (D) Example FCM plots and percentage of Ki67 in splenic PD-L1 + PMN-MDSCs ( n = 8). (E) Example FCM plots and percentage of PD-L1 in pulmonary PMN-MDSCs ( n = 6). (F) Schematic of CLP modeling, Adv-shRNA ( S100a9 ) treatment, and tissue collection in WT mice. (G) Example FCM plots and percentage of PD-L1 in splenic PMN-MDSCs ( n = 9). (H) Schematic of CLP modeling, Adv-shRNA ( S100a9 ) treatment, and tissue collection in Kaede-tg mice. (I) Example FCM plots and percentage of Kaede red + in pulmonary PD-L1 + PMN-MDSCs ( n = 7 to 8). (J) FCM analysis using t-SNE algorithm showing expressions of PD-1, Lag3, and CD200 in pulmonary AMs ( n = 9 to 10). Values are shown as mean ± SD; statistical testing was determined using Student t test. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

Article Snippet: Membranes were incubated overnight at 4 °C with antibodies against C1qa (1:1,000, Proteintech, #11602-1-AP), LAG3 (1:1,000, Abclonal, #A2996), CD200 (1:1,000, Abclonal, #A23050), S100A8 (1:1,000, Abclonal, #A15315), S100A9 (1:1,000, Abclonal, #A9842), Wnt5A (1:1,000, Zen Bio, #619919), LEF1 (1:500, Proteintech, #14972-1-AP), KLF9 (1:1,000, Abclonal, #A7196), PD-1 (1:1,000, Abclonal, #A11973), PD-L1 (1:1,000, Abclonal, #A21443), IL-6 (1:1,000, Abcam, #ab229381), TFDP1 (1:1,000, Abclonal, #A5422), IL-10 (1:1,000, Abclonal, #a12255), TGF-β (1:1,000, Abcam, #ab64715), TNF-α (1:1,000, Abclonal, #A11534), PCNA (1:500, Proteintech, #10205-2-AP), or β-actin (1:4,000, Proteintech, #66009-1-Ig).

Techniques: Western Blot, shRNA